Literature DB >> 2972176

Percutaneous transluminal renal angioplasty in the patient with a solitary functioning kidney.

D N McDonald1, D C Smith, M D Maloney.   

Abstract

Since the introduction of percutaneous transluminal renal angioplasty, it has become established as an effective treatment for the correction of renovascular hypertension or the preservation of renal function. However, there has been a general reluctance to use it or other interventional procedures in any patient with a solitary functioning kidney. We attempted renal angioplasty in 11 patients each of whom had a solitary functioning kidney. All 11 had had either a previous contralateral nephrectomy or an autonephrectomy from chronic arterial occlusion. The patients ranged in age from 42 to 81 years. In nine of the 11 patients, a catheter was negotiated across the stenosis, and the lesion was dilated successfully. In two, the lesion could not be crossed. In the group of nine patients whose lesions were dilated successfully, clinical follow-up (2-180 weeks) revealed that hypertension was cured in four and improved in five. Of the two patients in whom angioplasty was not possible, one required emergency renal bypass surgery and the other had no change in renal status. Renal function test results after the procedure were variable and did not correlate with decreases in blood pressure. We conclude that percutaneous renal angioplasty is a satisfactory alternative to surgery for the treatment of renovascular hypertension or the preservation of renal function in a patient with a solitary functioning kidney.

Entities:  

Mesh:

Year:  1988        PMID: 2972176     DOI: 10.2214/ajr.151.5.1041

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  1 in total

1.  [Status of the captopril test in the diagnosis of hypertension].

Authors:  S Degenhardt; H Friedrich; G Wambach; J H Fischer; W Gross-Fengels; A Linden; K F Neufang; W Hummerich
Journal:  Klin Wochenschr       Date:  1989-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.